Search clinical trials for: azacitidine lenalidomide

Total 1845 results

Sun Yat-sen University

Recruiting

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell Lymphoma

China
Celgene

Active, not recruiting

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Multiple Myeloma

Netherlands, Belgium, Denmark, Germany, United Kingdom, France, Norway, Spain, Austria, Ireland, Italy, Sweden
Leslie Andritsos
Celgene Corporation

Completed

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States
Celgene

Terminated

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

Multiple Myeloma

China
Nordic MDS Group

Completed

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

AML | MDS

Denmark, Norway, Sweden
National Health Research Institutes, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Not yet recruiting

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Peripheral T-cell Lymphomas (PTCL)

Taiwan
Celgene

Completed

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States, Spain, Germany, France, Italy, Canada, United Kingdom
Center for International Blood and Marrow Transplant...
Celgene Corporation; National Marrow Donor Program

Completed

Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma (07-REV)

Multiple Myeloma

United States
Technische Universität Dresden
Celgene Corporation

Terminated

Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (LENAMAINT)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

Germany
Sutter Medical Foundation

Completed

Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders

Autism
Sanofi

Completed

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

Open Angle Glaucoma -Ocular Hypertension

United States
Mati Therapeutics Inc.

Withdrawn

A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Glaucoma
University of California, San Diego
Pfizer; Celgene Corporation

Completed

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Novartis Pharmaceuticals

Terminated

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

High Risk MDS

United States
Centre Hospitalier Universitaire de Nice

Recruiting

Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven (VENETACIBLE)

Acute Myeloid Leukemia

France
Translational Research in Oncology
Celgene

Terminated

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Epithelial Ovarian Cancer

United States
Columbia University
Celgene

Terminated

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Lymphoma | Hodgkin Lymphoma | Lymphoid Malignancies | Non-hodgkin Lymphoma

United States
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Acute Myeloid Leukemia (AML) | Acute Lymphocytic Leukemia (ALL)

United States
St. Joseph's Hospital and Medical Center, Phoenix
Texas Tech University

Not yet recruiting

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Cognitive Dysfunction | Neurodegenerative Disease, Hereditary | Cognitive Impairment, Mild | Amyloid Plaque | Inflammation, Brain
MorphoSys AG

Completed

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Diffuse Large B-cell Lymphoma

Belgium, Germany, United States, Austria, Czechia, France, Italy, Portugal, Spain
Celgene

Completed

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Leukemia, B-Cell, Chronic

Canada, United States, Germany, Italy, Spain, Sweden, United Kingdom
Ruijin Hospital

Unknown

R2 in the Treatment of Follicular Lymphoma

Follicular Lymphoma

China
Innate Pharma

Completed

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse (KIRIMID)

Patients With Multiple Myeloma Experiencing a | First or Second Relapse

United States
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia

Myelodysplasia

Australia
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Glioblastoma | Gliosarcoma | Malignant Gliomas

United States
University Hospital, Toulouse
Dana-Farber Cancer Institute; Celgene Corporation; Janssen-Cilag Ltd.

Completed

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)

Myeloma

France
ZePing Zhou
Guizhou Provincial People's Hospital; Second Xiangya Hospital of Central South... and other collaborators

Recruiting

Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

Acute Myeloid Leukemia

China
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Columbia University
Celgene Corporation

Active, not recruiting

Revlimid in Transfusion Dependent Patients

Myelodysplastic Syndrome

United States
The Lymphoma Academic Research Organisation
Celgene Corporation

Completed

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma (CLEAR)

Relapsed/Refractory B-cell Lymphoma

France
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Southern Europe New Drug Organization
Celgene Corporation

Unknown

Lenalidomide and Paclitaxel in Advanced Solid Tumors

Advanced Solid Tumors

Switzerland, Italy
M.D. Anderson Cancer Center
Sanofi

Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Multiple Myeloma

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

DLBCL

China
Peking Union Medical College Hospital

Recruiting

Lenalidomide in the Treatment of Mucosal Behçet's Syndrome

Oral Ulcer

China
Seoul National University Hospital

Recruiting

GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Relapsed/Refractory Diffuse Large B Cell Lymphoma

Korea, Republic of
Xencor, Inc.

Terminated

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL

Diffuse Large-cell B-cell Lymphoma

Spain, United States, France
Celgene

Completed

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Myelodysplastic Syndromes

United States, Germany
University Hospital, Toulouse
Celgene; Intergroupe Francophone du Myelome

Completed

Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02)

Myeloma

France, Belgium, Switzerland
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

Kidney Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Unknown

Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence

Efficacy and Safety | HSCT

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML

Secondary Acute Myeloid Leukemia

China
National Cancer Institute (NCI)

Active, not recruiting

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Cutaneous T-Cell Lymphoma | Peripheral T-Cell Lymphoma | Mature T-cell Malignancies | Relapsed/ Refractory T-cell Malignancies

United States
Yale University

Completed

Window Trial 5-aza in HNSCC, T-tare

Head and Neck Squamous Cell Carcinoma

United States
Celgene

Completed

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Multiple Myeloma

Ukraine, Russian Federation
King's College Hospital NHS Trust

Completed

The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

Myelodysplastic Syndromes

United Kingdom
National Cancer Institute (NCI)

Completed

CC-5013 in Treating Patients With Recurrent Glioma

Brain and Central Nervous System Tumors

United States

Search clinical trials for: azacitidine lenalidomide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations